Fund shareholders of Biogen Inc
ISIN US09062X1037 · United States · LEI W8J5WZB5IY3K0NDQT671
- Fund shareholders
- 831
- Of which ETFs
- 244 587 other funds
- Value held
- 12.4B $ 1.3B SEK · 50.6M €
- Share of capital
- 45.9 % of 147.8M shares on Jul 27, 2026
831 funds hold this company. This table lists the 827 that declare it in a regulatory filing. The other 4 publish their holdings in their own reports. They are not in the table.
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Cyber Hornet S&P 500 & XRP 75/25 Strategy ETF Cyber Hornet Trust | 1 | 183.3 $ | 0.04 % | 0.00 % | as of Mar 31, 2026 ↗ |
| FONDMAPFRE BOLSA AMERICA, FI MAPFRE ASSET MANAGEMENT, SGIIC, S.A. | 13.8M € | 2.21 % | as of Dec 31, 2025 ↗ | ||
| BBVA MEGATENDENCIA TECNOLOGÍA, FI BBVA ASSET MANAGEMENT, S.A., SGIIC | 9.3M € | 0.57 % | as of Dec 31, 2025 ↗ | ||
| MERCHFONDO, FI ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 6M € | 3.45 % | as of Dec 31, 2025 ↗ | ||
| MERCH-UNIVERSAL, FI ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 3.8M € | 4.15 % | as of Dec 31, 2025 ↗ | ||
| IBERCAJA SANIDAD, FI IBERCAJA GESTION, SGIIC, S.A. | 3.2M € | 1.06 % | as of Dec 31, 2025 ↗ | ||
| KUTXABANK BOLSA NUEVA ECONOMIA, FI KUTXABANK GESTION, SGIIC, S.A. | 2.9M € | 0.53 % | as of Dec 31, 2025 ↗ | ||
| BBVA USA DESARROLLO, FI BBVA ASSET MANAGEMENT, S.A., SGIIC | 2.6M € | 0.40 % | as of Dec 31, 2025 ↗ | ||
| FONDMAPFRE GLOBAL, FI MAPFRE ASSET MANAGEMENT, SGIIC, S.A. | 1.9M € | 0.54 % | as of Dec 31, 2025 ↗ | ||
| MERCH-FONTEMAR, FI ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 1.8M € | 3.29 % | as of Dec 31, 2025 ↗ | ||
| MORINVEST, SICAV, S.A. BBVA ASSET MANAGEMENT, S.A., SGIIC | 946K € | 0.14 % | as of Dec 31, 2025 ↗ | ||
| FONDMAPFRE RENTA MIXTO, FI MAPFRE ASSET MANAGEMENT, SGIIC, S.A. | 625K € | 0.36 % | as of Dec 31, 2025 ↗ | ||
| BBVA USA DESARROLLO CUBIERTO, FI BBVA ASSET MANAGEMENT, S.A., SGIIC | 558K € | 0.40 % | as of Dec 31, 2025 ↗ | ||
| BINDEX USA INDICE, FI BBVA ASSET MANAGEMENT, S.A., SGIIC | 515K € | 0.04 % | as of Dec 31, 2025 ↗ | ||
| ING DIRECT FONDO NARANJA STANDARD & POOR´S 500, FI AMUNDI IBERIA, SGIIC, S.A. | 477.5K € | 0.05 % | as of Dec 31, 2025 ↗ | ||
| FONDMAPFRE ELECCION MODERADA, F.I. MAPFRE ASSET MANAGEMENT, SGIIC, S.A. | 453.5K € | 0.13 % | as of Dec 31, 2025 ↗ | ||
| FONDMAPFRE ELECCION PRUDENTE, F.I. MAPFRE ASSET MANAGEMENT, SGIIC, S.A. | 429.5K € | 0.14 % | as of Dec 31, 2025 ↗ | ||
| DUNAS SELECCIÓN USA ESG CUBIERTO FI DUNAS CAPITAL ASSET MANAGEMENT S.G.I.I.C., S.A. | 274.4K € | 0.08 % | as of Dec 31, 2025 ↗ | ||
| FONDMAPFRE ELECCIÓN DECIDIDA, F.I. MAPFRE ASSET MANAGEMENT, SGIIC, S.A. | 211.4K € | 0.21 % | as of Dec 31, 2025 ↗ | ||
| RENTA 4 UNIVERSAL, FI RENTA 4 GESTORA, S.G.I.I.C., S.A. | 149.8K € | 1.95 % | as of Dec 31, 2025 ↗ | ||
| TOP CLASS HEALTHCARE, FI RENTA 4 GESTORA, S.G.I.I.C., S.A. | 149.8K € | 1.12 % | as of Dec 31, 2025 ↗ | ||
| SIGMA INVESTMENT HOUSE HEALTHCARE, FI ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 137.7K € | 0.35 % | as of Dec 31, 2025 ↗ | ||
| COMPROMISO MEDIOLANUM, FI MEDIOLANUM GESTION, S.G.I.I.C., S.A. | 126.6K € | 0.31 % | as of Dec 31, 2025 ↗ | ||
| BBVA BOLSA INDICE USA (CUBIERTO), FI BBVA ASSET MANAGEMENT, S.A., SGIIC | 110K € | 0.04 % | as of Dec 31, 2025 ↗ | ||
| ESPECTRUM I ESTRATEGIES INVESTMENT, S.A. SICAV GESALCALA, S.A., S.G.I.I.C. | 82.4K € | 1.90 % | as of Dec 31, 2025 ↗ | ||
| BINDEX USA SCREENED ÍNDICE (CUBIERTO), FI BBVA ASSET MANAGEMENT, S.A., SGIIC | 51K € | 0.06 % | as of Dec 31, 2025 ↗ | ||
| GESTION BOUTIQUE VIII, FI GESTION BOUTIQUE VIII / VETUSTA INVERSIÓN ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 21.4K € | 0.90 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Invesco Biotechnology & Genome ETF Invesco Exchange-Traded Fund Trust | 5.05 % | as of Apr 30, 2026 ↗ |
| MERCH-UNIVERSAL, FI ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 4.15 % | as of Dec 31, 2025 ↗ |
| VanEck Biotech ETF VanEck ETF Trust | 3.72 % | as of Mar 31, 2026 ↗ |
| iShares Neuroscience and Healthcare ETF iShares Trust | 3.67 % | as of Apr 30, 2026 ↗ |
| iShares Health Innovation Active ETF BlackRock ETF Trust | 3.63 % | as of Apr 30, 2026 ↗ |
| First Trust Nasdaq Pharmaceuticals ETF First Trust Exchange-Traded Fund VI | 3.62 % | as of Mar 31, 2026 ↗ |
| First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund | 3.47 % | as of Mar 31, 2026 ↗ |
| MERCHFONDO, FI ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 3.45 % | as of Dec 31, 2025 ↗ |
| The Free Markets ETF Tidal Trust I | 3.40 % | as of Feb 28, 2026 ↗ |
| Alger Mid Cap 40 ETF Alger ETF Trust | 3.32 % | as of Mar 31, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 766 | +47 | 67,078,108 | +6.5 % |
| 2026Q1 | 719 | -1 | 62,971,523 | +5.5 % |
| 2025Q4 | 720 | +20 | 59,708,137 | -2.5 % |
| 2025Q3 | 700 | -22 | 61,228,423 | -2.0 % |
| 2025Q2 | 722 | +8 | 62,471,837 | -1.2 % |
| 2025Q1 | 714 | -49 | 63,217,302 | -2.5 % |
| 2024Q4 | 763 | -14 | 64,810,261 | -3.6 % |
| 2024Q3 | 777 | -4 | 67,231,656 | +1.9 % |
| 2024Q2 | 781 | -46 | 65,957,473 | +7.9 % |
| 2024Q1 | 827 | -55 | 61,122,879 | +2.1 % |
| 2023Q4 | 882 | 59,883,539 |
Institutional managers
987 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| BlackRock, Inc. | 15,974,601 | 2.9B $ | as of Mar 31, 2026 |
| PRIMECAP MANAGEMENT CO/CA/ | 14,757,607 | 2.7B $ | as of Mar 31, 2026 |
| FMR LLC | 12,807,541 | 2.3B $ | as of Mar 31, 2026 |
| STATE STREET CORP | 7,167,922 | 1.3B $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 4,342,602 | 793.4M $ | as of Mar 31, 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 2,961,641 | 543M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 2,170,940 | 398M $ | as of Mar 31, 2026 |
| JPMORGAN CHASE & CO | 2,016,009 | 378.1M $ | as of Mar 31, 2026 |
| AQR CAPITAL MANAGEMENT LLC | 1,923,557 | 346.2M $ | as of Mar 31, 2026 |
| Invesco Ltd. | 1,745,255 | 320M $ | as of Mar 31, 2026 |
| Boston Partners | 1,700,078 | 311.7M $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 1,446,579 | 265.2M $ | as of Mar 31, 2026 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1,377,568 | 252.5M $ | as of Mar 31, 2026 |
| Legal & General Group Plc | 1,349,832 | 247.5M $ | as of Mar 31, 2026 |
| T. Rowe Price Investment Management, Inc. | 1,160,989 | 212.8K $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 1,156,369 | 212M $ | as of Mar 31, 2026 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,149,394 | 210.7M $ | as of Mar 31, 2026 |
| VAN ECK ASSOCIATES CORP | 1,079,861 | 198K $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 1,079,119 | 197.9M $ | as of Mar 31, 2026 |
| DEUTSCHE BANK AG\ | 1,063,828 | 195M $ | as of Mar 31, 2026 |
| GOLDMAN SACHS GROUP INC | 1,051,094 | 192.7M $ | as of Mar 31, 2026 |
| Pictet Asset Management Holding SA | 913,328 | 168.3M $ | as of Mar 31, 2026 |
| Point72 Asset Management, L.P. | 809,617 | 148.4M $ | as of Mar 31, 2026 |
| Alyeska Investment Group, L.P. | 805,050 | 147.6M $ | as of Mar 31, 2026 |
| Amundi | 790,827 | 145M $ | as of Mar 31, 2026 |
Declared shareholders of Biogen Inc
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| FMR LLC and 1 other | 11.30 % | 16,652,975 | as of May 29, 2026 · SCHEDULE 13G |
| Vanguard Capital Management | 7.48 % | 10,989,562 | as of Mar 31, 2026 · SCHEDULE 13G |
Funds holding the debt of Biogen Inc
194 funds declare 386 bond lines of this company. The table shows the 25 largest holdings. The amount is the one the fund files. It is not a share of the debt, because no regulator publishes the amount outstanding in open access.
Cite this page
Titelia. "Fund shareholders of Biogen Inc". https://titelia.com/en/stocks/biogen-inc-US09062X1037